Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously for the treatment of severe SARS-CoV-2 infections.
Description: Success of SARS-CoV-2 specific T cell manufacturing is defined as production of >200,000 T cells per donor. The success rate will be summarized descriptively.
Measure: Success rate in production of SARS-CoV-2 specific T cells from convalescent donor Time: Two weeks (The expected duration of donor participation is 2 weeks)